S-217622
ACTIV-2d/A5407
Phase 3 small_molecule completed
Quick answer
S-217622 for SARS-CoV-2 Infection is a Phase 3 program (small_molecule) at Shionogi B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Shionogi B.V.
- Indication
- SARS-CoV-2 Infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed